Aurora, Colorado | Info@pcmarkers.com

Our Panel of Experts

E. David Crawford, MD

Dr. David Crawford is the distinguished Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus. He is an active clinician, researcher, and teacher. He has been recognized as one of the Best Doctors in America, one of the Best Cancer Doctors, one of the Top 20 Urologists in the county by Men's Health Magazine, and recently selected as the Healthcare Provider of the Year in the Denver Metro Area by The Denver Business Journal. In addition, he is the recipient of more than 95 research grants in the diagnosis and treatment of prostate cancer, metastatic prostate cancer, hormone refractory prostate cancer, benign prostatic hyperplasia (BPH), advanced bladder cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 600 published articles, contributed to nearly 100 educational books and provided thousands of educational talks for patients and physicians.

 

In an effort to raise awareness and education about prostate health, Dr. Crawford founded and is the current Chairman of the Prostate Conditions Education Council, a non-profit organization which is responsible for reaching an average of 400 million people each year with education and awareness information.

 

On prostate cancer and men's health issues, his involvement in the national prostate cancer arena has been widely recognized and he is often requested to act as an educator, speaker, participate in advisory boards, review research or serve as a legal expert.

 

Dr. Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, American Urological Association (AUA), and the American Association for the Advancement of Science.

Neal D. Shore, MD

Neal D. Shore, MD, FACS

Director, CPI, Carolina Urologic Research Center

Atlantic Urology Clinics

Myrtle Beach, South Carolina

 

Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.

Dr. Shore has conducted more than 250 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network,Society of Urologic Oncology Clinical Trials Consortium, Secretary-Treasurer, and is President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee; he is currently a member of the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor),  Urology Practice,World Journal of Urology, and serves as Editor, Everyday Urology. He has more than 125 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, European Urology,Journal Urology, Urology, BJUI,PCPD, and numerous other high impact scientific journals.

 

A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6 month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.

Daniel P. Petrylak, MD

As Professor of Medicine and Urology at Yale School of Medicine, Dr. Daniel P. Petrylak is a pioneer in the research and development of new drugs and treatments to fight prostate, bladder, kidney and testicular cancer. For patients fighting these types of cancers, Petrylak finds recent developments in the field of immunotherapy particularly promising. “Up until recently, bladder cancer had not seen any major advancement in more than 30 years,” he says. “Studies are ongoing, but interim results are exciting so far.”

 

At the Smilow Cancer Hospital, Dr. Petrylak’s position as a national leader on clinical trials for men with prostate and bladder cancer has opened up a world of treatment options for patients in New England. “We offer the latest investigational drugs for these conditions, while providing the highest level of care,” he says.

 

Dr. Petrylak received his MD from Case Western Reserve University School of Medicine and joined the Yale faculty in 2012. In addition to his role as professor, he is also the co-director of the Signal Transduction Research Program at Yale Cancer Center, which studies how cancer stem cells are regulated in the body and communicate with surrounding tissue. Roughly 40 physicians and scientists in the program work together to develop the best methods for matching patients with the appropriate cancer drugs.

One of Dr. Petrylak’s key goals is to continue to successfully translate basic research into clinical practice. “One of the most significant accomplishments in my career was moving docetaxel (an antineoplastic agent) therapy for the most advanced form of prostate cancer from phase I to III,” he says. “We ran a trial which supported its approval for the most advanced form of prostate cancer.”

 

Dr. Petrylak currently serves as either the principal investigator or co-principal investigator on seven Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. To date, he has authored more than 100 peer-reviewed articles on prostate and bladder cancer research.

Leonard G. Gomella, MD, FACS

Dr. Leonard Gomella is the Bernard W. Godwin, Jr. Professor of Prostate Cancer and Chairman of the Department of Urology at the Sidney Kimmel Medical College. After general surgery and Urology training at the University of Kentucky he completed a fellowship in the Surgery Branch of the National Cancer Institute. He joined the Jefferson faculty in 1988 and was appointed Chair in 2002. He serves as Senior Director for Clinical Affairs for the Sidney Kimmel Cancer at Jefferson, Clinical Director of the SKCC Network and Urology Chair for NRG. He is currently President of the Society of Urologic Oncology.

Dr. Gomella is involved in translational basic science and clinical research in the development of new diagnostic techniques and treatments for prostate and bladder cancer through the SKCC as Co-Leader of the Biology of Prostate Cancer Program. He has given over 500 presentations nationally and internationally and written over 400 papers, chapters and monographs. He is a consultant to over 2 dozen journals in the field of urology and oncology and in 2010 became Editor-in-Chief of the “Canadian Journal of Urology”. Dr. Gomella has also authored and edited 63 editions of 17 different books for medical students, residents, and practicing physicians. In 2015 he received a “Distinguished Contribution Award” from the AUA and Jefferson honored him with the “Jefferson Achievement Award in Medicine”. 

Neil H. Baum, MD

Neil H. Baum, MD, is Professor of Clinical Urology at Tulane Medical School in New Orleans, Louisiana.

 

Dr. Baum is the author of Marketing Your Clinical Practice-Ethically, Effectively, and Economically, which is in its 4th edition, has sold over 175,000 copies and has been translated into Spanish.  He has also written The Complete Business Guide To a Successful Medical Practice, which was published in 2015. 

 

Dr. Baum was the columnist for American Medical News for more than 25 years.  Dr. also Baum wrote the popular column, The Bottom Line, for Urology Times for more than 20 years. 

 

Dr. Baum focuses on patient education and has written extensively on enhancing communication with patients and their families.  Dr.Baum has made an effort to simplify the communication with patients who have concerns about prostate cancer screening, prostate biopsies, genomic testing using the new prostate cancer markers, and helping patients with a decision to have their prostate cancer managed with active surveillance. 

 

He is a requested speaker each year to the Practice Management seminar for the AUA where he discusses techniques to make a urology practice more efficient and more productive.  He has written 8 books on practice management and over 250 peer reviewed articles on various urologic topics including prostate cancer. 

Francisco G. La Rosa, MD

Dr. Francisco G. La Rosa is an Associate Professor in the Department of Pathology at the University of Colorado Anschutz Medical Campus and member of the University of Colorado Cancer Center. He is an active clinician, researcher and teacher, board certified in anatomic and clinical pathology, specialized in genitourinary, renal and heart pathology, and expert in pathology informatics. Dr. La Rosa has more than 85 publications in referee journals and has several Web sites for the teaching of pathology.

Dr. La Rosa is an active member of many national and international organizations, including the College of American Pathologists, The American Urological Association, American Telemedicine Association, Peruvian American Medical Association, and Catholic Medical Association.

 

As a researcher, he has participated as a collaborator in several research grants in genitourinary pathology, is a member and study coordinator at the Southwest Oncology Group (SWOG), Genitourinary Committee, and a close research collaborator with Dr. David Crawford in cutting edge technology for the diagnosis and treatment of prostate cancer.

 

As a Teaching Scholar at the University of Colorado, he lectures medical and dental students, as well as pathology residents and fellows, with several awards for teaching excellence.  As an international scholar, he is an Honorary Professor at the Medical School Hipolito Unanue, National University "Federico Villarreal", in Lima, Peru, cofounder and Past-President of the Asociación Iberoamericana de Telesalud y Telemedicina (AITT), cofounder of the Asociación Peruana de Telesalud y Telemedicina, founder and Editor in Chief of the journal "Revista de la AITT (ISSN 2411-3840)," and member of several international scientific committees and editorial boards of pathology journals.

Michael Leapman, MD

Dr. Michael Leapman is an Assistant Professor in the Department of Urology at Yale University School of Medicine. He specializes in urologic oncology, with a clinical and research interest in prostate cancer. He graduated from Cornell University, and attended medical school at the University of Maryland.

 

He completed his Urology Residency at the Mount Sinai School of Medicine and a two year Urologic Oncology fellowship at the University of California San Francisco.

 

He has authored numerous research publications in the field of prostate cancer, and risk stratification, and serves as a reviewer for several high impact Urology journals including European Urology, and the Journal of Urology.

.

Tim Langford, MD

Dr. Tim Langford is the president of Arkansas Urology in Little Rock, Arkansas.  He is also an Adjunct Clinical Assistant Professor in the Department of Urology at the University of Arkansas Medical Sciences Campus (UAMS).  Dr. Langford graduated from UAMS in 1988 and completed his urology residency at UAMS in 1993.

 

Dr. Langford practices general urology and has special interests in male incontinence, prosthetics and robotic surgery.  He helped establish and serves as a physician champion in the Arkansas Urology Advanced Prostate Cancer Center of Excellence.  He is currently the President-Elect of the South Central Section of the AUA.

Paul Arangua, MPH

Paul Arangua is an integral member of Dr. Crawford's research team and the Director of Clinical Research in the department of urologic oncology at the University of Colorado, Anschutz Medical Campus. Paul has over 10 years experience conducting clinical research, and specializes in a multitude of prostate cancer diagnostic and treatment methods, including prostate cancer molecular biomarker research, prostate cancer screening, 3D diagnosis utilizing 3D staging biopsy as well as MRI fusion, and targeted treatment of prostate cancer, to name a few. Paul studied at the the University of Colorado at Denver and the Colorado School of Public Health at the Anschutz Medical Campus where he received his masters degree in Public Health Epidemiology. 

Jessica Myers-Schecter

Jessica Myers-Schecter publishes Prostatepedia, a monthly health journal that features conversations with leading scientists, researchers, and patient advocates for patients, their loved ones, and health professionals in the United States, Canada, Europe, Australia, and India.

 

With over 200 interviews under her belt, Jessica strives to provide perspective and insight into the ongoing dialogue between patients and the health professionals who care for them.

 

Jessica received a MFA in Writing from American University and a BA in English from the University of Pennsylvania. She serves on the Board of the Penn Silicon Valley Alumni Club.

.

Please reload